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Abstract 
Numerous studies have shown 
estrogen to be vasoactive in various 
circulations. Our objective was to 
determine the eHect of estrogen on 
isolated bovine coronary arteries and 
the possible mechanism. Bovine 
coronary arteries, precontracted with 
thromboxane mimetic u46619 were given 
doses (0.0 l-30!-IM) of l7B-estradiol in 
the presence and absence of 
endothelium and these inhibitors: 
lOIJM indomethacin (cyclooxygenase 
inhibitor), lOIJM methylene blue 
(inhibits soluble guanylate cyclase), 
l OOIJM nitro-L-arginine (inhibits nitric 
oxide synthesis), l OOIJM 
isobutylmethylxanthine 
(phosphodiesterase inhibitor) and 
30!-IM mifepristone (Ru3a4a6 steroid 
receptor antagonist). Our results 
indicated that, estrogen, in the 
highest concentration used (301JM), 
elicited an acute dose-dependent 
relaxation of bovine coronary arteries 
from 4%-68% (n = lS). No major 
difference in relaxation was observed 
between coronary arteries with or 
without endothelium, indicating that 
the mechanism was endothelium-
independent. Indomethacin, 
nitro-L-arginine and methylene blue 
did not alter this relaxation, 
suggesting that relaxant 
prostaglandins, 1-arginine products 
and cGMP are not involved 
(n = ll-l6), isobutylmethylxanthine 
enhanced relaxation from 20%-40% 
(n= lS p < O.Ol), suggests a role for 
cAMP. Furthermore, mifepristone 
reduced the relaxation by more than 
50% (n= lS p<O.OS) consistent with 
the role for estrogen receptors. Based 
on our study, estrogen causes a dose-
dependent relaxation of bovine 
coronary arteries that does not 
appear to utilize endothelium, 
prostaglandins, cGMP or arginine 
products, but may involve cAMP and 
estrogen receptors. This study may 
help justify treating myocardial 
ischemia with estrogen. 
Introduction 
Although the cardioprotective 
effect of estrogen is well recognized 
(1), mechanisms by which this 
steroid hormone provides its effect 
are not fully understood . The 
cardiovascular protective action of 
estrogen is reportedly mediated by 
effects on lipoprotein metabolism, 
hemostatic factors and by the direct 
effect on the vessel wall. 
One characteristic of estrogen 
that may be important in 
cardioprotection is its effect on 
vascular tone generation. Evidence 
of this would be estrogen 
improvement of coronary blood flow 
in both postmenopausal women (2) 
and monkeys with coronary 
atherosclerosis (3) . The specific 
mechanism by which estrogen affects 
vascular tone still remains unclear. 
Rabbit aorta data have shown that 
estrogen promotes and enhances 
endotheli al-dependent relaxation 
and contraction (4,5). Additionally, 
an increase in endotheli al nitric 
oxide (6) and prostacycline (7) 
release has been demonstrated in 
rabbit coronary arteries and rat 
aortas respectively. There is also the 
possibility that estrogen may 
influence vascular relaxation via 
decreasing endothelium-derived 
vasoconstrictor prostaglandins, 
thomboxanes (5), superoxide 
radicals and endothelines (8) . 
Conversely, endothelium-
independent relaxations are 
possible, as has been shown in the 
rabbit coronary artery (9). This 
relaxation and that in guinea pig 
cardiac myocytes (10) are thought 
to be due to calcium channel 
blocking properties of the hormone. 
In this study, we investigated the 
vasoactivity of acute estrogen 
treatment in isolated bovine 
coronary arteries to add evidence in 
support of estrogen as an important 
cardiovascular agent. We also 
attempted to define the specific 
mechanisms responsible for this 
vasoactivity by employing the use of 
various pharmacological agents. 
Materials and methods 
Tone measurements 
Bovine hearts were obtained from 
a local slaughterhouse right after 
s laughter. The left anterior 
descending coronary arteries were 
cut out and during transport they 
were kept in an ice-cold phosphate 
buffer (mM/liter) solution of: 
Glucose 11.09 mM/liter, NaC1125, 
KC12. 7, Tris 23.8 and CaC12 2.0. 
The vessels were cleaned carefully 
from surrounding tissue and cut, 
with a new scalpel, into rings of 2 to 
3 mm in diameter and 2 mm in 
length. Care was taken to avoid 
damage to the endothelium. Some of 
the rings were denuded of 
endothelium by gentle rubbing of 
the lumen with the wooden handle 
of a cotton swab for about 30 sec. 
The arterial rings were then 
mounted on wire hooks attached to 
force displacement transducers 
(T 43-05, Colbourn Instruments) for 
measuring changes in isometric 
force using methods already 
described (11). Thereafter, vessels 
were incubated in 10 ml baths 
(Metro Scientific) with Krebs-buffer 
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(pH 7.4) solution containing 
(mM/liter): 118 NaCI, 4. 7 KCI, 1.5 
CaCL2, 25 NaHC03, 1.1 MgS04, 1.2 
KH2P04 and 5.6 glucose. The baths 
were individually thermostated 
(3rC), and gassed with 95% 0/ 
balanced air. Rings were adjusted to 
Sg passive tension, which was found 
to be the optimal passive force for 
maximal contraction. Changes in 
force were recorded on a Col bourn 
computer-based recording system. 
After a two-hour equilibration at 
the optimal passive tension, the 
vessels were depolarized with Krebs-
bicarbonate solution containing KCI 
(123M/liter) in place of NaCI. This 
treatment produces maximal 
contraction and enhances the 
reproducibility of subsequent 
contractions. Additionally, it allows 
the evaluat ion of the viability of 
vessel rings. The arteries were then 
re-equilibrated with Krebs-
bicarbonate for 15 min. before 
conducting experiments. The removal 
of endothelium in some artery rings 
was confirmed by examining the 
effect of 0.01-1 (M acetylcholine on 
arteries precontracted with 0.1-3(11/1 
5-hydroxytryptamine (SHT). 1 
Endothelium-denuded arteries 
contracted at the largest dose of 
acetylcho line and relaxations were 
not observed. 
Exposure to estradiol 
Vessels were first precontracted 
to a submaximal average tone of 1.5 
(0.3g using the thromboxane 
mimetic U46619 (10-100(M/liter). The 
dose of u46619 was adjusted to 
produce similar tone in all rings. 
Tone was allowed to achieve a 
steady state level; then, cumulative 
doses of estradiol (0.01-3011M/liter) 
were added to the organ baths, 
allowing a 5 min. period between 
doses or maximum response. After 
the highest dose was added, the 
experiment was completed. 
In order to elucidate specific 
mechanisms q( relaxation, the same 
experiments were again performed 
in the presence of a variety of 
pharmacological inhibitors for 15 
min. These agents were chosen to 
block specific mechanisms that might 
contribute to specific estrogen 
effect. The concentrations and 
names of the agents were as follows: 
10mM/L indomethacin (Indo, 
cyclooxygenase inhibitor), 
10mM/L methylene blue (MB inhibits 
soluble guanylate cyclase), 100mM/L 
nitro-L-arginine (NLA inhibits nitric 
oxide synthesis), 1 mmol/L 
isobutylmethylxanthine (IBMX, 
cAMP phosphodiesterase inhibitor) 
or 30mM/L mifepristone (RU38486 , 
steroid receptor antagonist). 
Dilutions of SHT were made in 
distilled deionized water and 10111 
aliquots were added to the 10 ml 
baths . Indomethacin was dissolved 
in absolute ethanol and 10111 from 
this solution was added to the bath. 
17~-estradiol was dissolved in ethyl 
alcohol to give a stock solution of 
lQ-2 M. Vehicle control with 10111 
ethyl alcohol was performed in five 
vessels without any significant 
effect. The stock solutions of U44619 
were made in ethyl alcohol and 
serial dilutions of stock were made 
in distilled deionized water. NLA, 
RU38.186, IBMX and MB were dissolved 
in distilled deionized water. NLA and 
IBMX were added in 100111 aliquots, 
whereas RU3x4x6 and MB were added 
in 30- and 1 O~tl aliquots respectively. 
Materials 
Indomethacin, methylene blue, 
nitro-L-arginine, SHT 
(5-hydroxytryptamine), 
isobutylmethylxanthine and 1 7~­
estradiol were purchased from Sigma 
Chemical Company(St. Louis). RU.1aG 
was generously provided by Roussel-
UCLAF (Romainville, France). U"4619 
was obtained from Cayman Chemical, 
Ann Arbor, MI. Other chemicals were 
analyzed reagent grade from Baker 
Chemical Co. (Phillipsburg, NJ). 
Statistical analysis 
All relaxations were calculated as 
percent Of U4,IGI9 induced tone. 
Nonpaired Student's t-test was 
utilized to compare responses 
between two groups. For multiple 
comparisons, analysis of variance 
(ANOV A) was performed followed by 
post-hoc Duncan's test. 
The accepted level of significance 
was p < 0.05. The number of 
experimental determinations (n) in a ll 
cases is equal to the number of 
animals from which a vessel ring was 
used for treatment or control group. 
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Results 
The addition of 0.0 1 -30~tmol/liter 
17~-estradiol to intact bovine 
coronary vessels precontracted with 
0.3~tmol/liter U46619 causes rapid and 
sustained concentration-dependent 
relaxation up to 68% (n=15). The 
relaxation is expressed as a 
percentage Of the U4GG19 induced 
tone before addition of the first 
estrogen dose. 
In addition, comparison of the 
magnitude of relaxation in response 
to 17~-estradiol at each 
concentration level between 
endothelium-intact and 
endothelium-denuded arteries did 
not show significant difference 
(Figure 1). Thus, in our study, 
17~-estradiol relaxation is not 
dependent on mediators released 
from the endothelium. 
Eovine coronary vessels 
pretreated with inhibitors [(a) 
10~tmol/liter indomethacin, (b) 
10011mol/liter nitro -L-arginine or (c) 
l011mol/liter methyl blue] when 
exposed to 0.01-30~101/liter 17~­
estradiol were relaxed in a similar 
manner to vessels in the control 
group without inhibitors 
pretreatment (n= 15). The lack of 
effects of these probes is shown in 
Figure 2 (a,b,c). These results suggest 
that relaxation of bovine coronary 
vessels to 17(-estradiol is not 
mediated by relaxant prostaglandins, 
!-arginine products, or cGMP. 
Pretreatment of bovine coronary 
vessels with 100mM/liter IBMX 
significantly enhanced the 17b-
estradiol-induced relaxation from 
20% to 40% (n= 15 p < 0.01) as shown 
in Figure 3. This is consistent with 
mediation by cAMP. 
Pretreatment of bovine coronary 
arteries with 3011M/liter RU384aG 
markedly reduced the relaxation to 
17~-estradiol by more than 50% 
(n = 15, p < 0.05) (Figure 4) suggesting 
a role for estrogen receptors in the 
mechanism of this relaxation. 
Discussion 
Animal studies in vitro and in 
vivo, as well as clinical studies, have 
suggested a variety of vascular 
effects and mechanisms of action of 
estrogen. This study shows that 
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Figure 1. Summary data showing 
relaxation response to 17P-estradiol 
in endothelium-intact (+EC) and 
endothelium denuded (EC-) bovine 
coronary arteries and the lack of 
effect of removal of endothelium on 
the relaxation. The vessels were 
precontracted with thromboxane 
mimetic U466 19. The relaxation is given 
as a percentage of the u46619 induced 
tone and values represent the means 
± S.E.M. in 15 determinations from 
15 different animals. 
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Figure 3. Summary data showing 
the enhancement of the relaxation 
from 20%-40% of endothelium-
intact coronary bovine arteries in 
response to 17P-estradiol after 
pretreatment with 1 OOf..lmoi/ L 
isobutylmethylxanthine (IBMX) 
suggest a role for cAMP 
(n=15, p<0.01 ). 
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Figure 4. Summary data showing 
the inhibitory effect of pretreatment 
with 30j.!moi/L mifepristone (RU38486) 
on relaxation produced by 1 7P-
estradiol in endothelium-intact 
bovine coronary arteries. Relaxation 
was reduced by more than 50% 
suggesting that estrogen receptors 
could be included (n=15, p<0.05). 
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Figures 2a,b,c. Summary data showing the lack of effect of pretreatment with (a) 1 Ojlmoi/L Indomethacin (Indo); 
(b) 1 OOj.!moi/L Nitro-L-Arginine (NLA); and (c) 1 Ojlmoi/L Methyl blue (MB) on the relaxation produced by estrogen in 
endothelium-intact bovine coronary arteries (n= 11-16). 
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17~-estradiol is a vasoactive 
hormone causing a rapid and 
sustained dose-dependent relaxation 
in precontracted bovine coronary 
arteries with and without 
endothelium. 
Our results did not indicate a 
difference in relaxation between 
endothelium-intact and 
endothelium-denuded coronary 
bovine arteries. Furthermore, 
nitro-1-arginine and indomethacin, 
inhibitors of endothelium-derived 
relaxing factor and prostaglandin 
production, did not affect the 
relaxation induced by 17~-estradiol 
in endothelium-intact coronary 
arteries. The lack of effect of these 
probes in our study suggests that 
relaxation does not appear to be 
mediated by the endothelium via 
nitric oxide production or 
arachidonic acid metabolites . 
Similar results have been reported 
in isolated rabbit coronary arteries 
(9) and on human atherosclerosis-
free epicardial arteries in vitro (12) . 
Another study showed that 
17~-estradiol relaxation in rabbit 
coronary artery rings was / 
endothelium and nitric oxide 
dependent under certain hormonal 
conditions such as acute estrogen 
withdrawal (13) . A report suggesting 
the existence of both endothelium-
dependent and endothelium-
independent mechanisms (but at 
higher concentrations), in isolated 
rabbit aortic rings has also been 
published (14) . 
Potentiation of 1 ?~-estradiol­
induced relaxation by IBMX, as 
shown in our study, suggests a role 
for cAMP. IBMX, a phosphodiesterase 
inhibitor, may decrease cAMP 
metabolism, increase cAMP level 
and, through cAMP-dependent 
protein kinase-mediated events (15), 
enhance 1 7~-estradiol relaxation of 
bovine coronary arteries. Other 
authors have only suggested that 
cAMP might be involved in the 
cellular response to estrogen (16). 
Methylene blue in our study did 
not affect relaxation to estradiol on 
the bovine coronary vessels, 
indicating no role for cGMP in this 
relaxation. However, in human 
coronary vessels, contents of both 
cAMP and cGMP were increased 
after exposure to estrogen (17). This 
could be explained by cross 
activation of cGMP-dependent 
protein kinase by cAMP. The 
elevation of cAMP within its 
physiological concentration range 
causes cGMP protein kinase-
dependent activation in pig coronary 
smooth muscle cells. Thus, the 
smooth muscle relaxant effects of 
either cAMP or cGMP could be 
mediated by cGMP protein kinase-
dependent activation (18) . 
It is unclear if the relaxation to 
17~-estradiol involves changes in 
calcium influx as has been 
suggested in experiments on rabbit 
coronary rings (9) and rat aortic 
rings (19). A primary effect of 
estrogen on coronary arteries may 
involve Ca2' and voltage-activated K· 
channels (16) . A portion of 
relaxation may reflect direct 
inhibition of potential sensitive and 
receptor-operated calcium channels 
as also has been suggested for 
uterine arteries (20). 
Cyclic AMP has been reported to 
increase the efflux of Ca2' from 
smooth muscle strips within minutes 
after its addition (21) . Since cAMP 
increases intracellular pH and 
increased pH stimulates the Ca2' 
pump, it is possible that such 
alkalization could be responsible for 
the cAMP-dependent increase of the 
Ca2' extrusion from the cell (22) . 
In our experiments, RU31l-186 
significantly inhibited the relaxation 
of bovine coronary vessels in 
response to 17~-estradiol, which is 
consistent with a need for estrogen 
receptor activation to elicit 
relaxation. Estrogen receptors have 
already been found in rat coronary 
artery smooth muscle cells (23), but 
the rapid vasorelaxation induced by 
high concentrations of estrogen 
excludes a genomic mechanism in 
the nucleus and indicates the 
possibility of non-genomic cell 
surface membrane binding sites 
(estrogen receptor) as have already 
been found at the outer surface of 
endometrial cells (24). 
The physiological nanomolar 
concentrations of 17~-estradiol were 
unable to produce significant 
relaxation of coronary arteries in 
vitro . The relaxation is achieved 
with concentrations approaching 
the micromolar range. The 
experimental physiological solution 
does not contain steroid binding 
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proteins . To more closely simulate 
physiological conditions, a higher 
concentration of free hormones is 
required . Thus, we used doses up to 
30J.1M/liter. 
Conclusion 
Based on our study, 17~-estradiol 
causes a dose-dependent relaxation 
in bovine coronary arteries that 
does not appear to utilize 
endothelium, prostaglandins, cGMP 
or arginine products, but may involve 
cAMP and possibly estrogen 
receptors . We have described a 
novel mechanism of estrogen 
relaxation that previously has only 
been suggested (19). The same 
mechanism of vasorelaxation was 
presented for progesterone, another 
steroid hormone, in placental 
human vessels in vitro (25). 
Since the 17~-estradiol-induced 
relaxation is endothelium-
independent, treatment by 17~­
estradiol may be used as a protection 
against my<,:>eardial ischemia in 
patients with atherosclerotic vessels . 
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